Synergy Healthcare

Bradenton, Florida 34209

4 studies enrolling now · 15 studies all time

What they study most

COVID-19, Chronic Kidney Diseases, Coronavirus Disease 2019, Covid19, Fatty Liver, Heart Failure With Reduced Ejection Fraction, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatohepatitis, NASH - Nonalcoholic Steatohepatitis, Non Alcoholic Steatohepatitis (NASH)

Studies at this site

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Recruiting now
• A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction — Recruiting now
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM — Completed
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) — Stopped early
• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Running, not enrolling
• The Prevent Severe COVID-19 (PRESECO) Study — Completed
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). — Stopped early
• A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection — Completed
• Sargramostim Use in COVID-19 to Recover Patient Health — Completed
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis — Status unconfirmed
• Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19 — Status unconfirmed